Novo Nordisk’s new India managing director takes charge amid heightened competition in the diabetes space. The Danish firm stays committed to bringing new products to this market at a faster clip and all eyes will be on the launch trajectory of therapies like semaglutide.

Sanofi has launched its next generation basal insulin, Toujeo, on the Indian market at a significantly reduced per unit price point versus Novo Nordisk’s Tresiba (insulin degludec), setting the stage for an interesting market expansion battle.

Life sciences firms are increasingly adopting new technologies like the metaverse and piloting use cases, although a "truly 3D immersive customer experience" may be some distance away. But 2024 could see an inflection point with increasing demand for certain metaverse applications, says a senior Indegene executive.